{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T04:31:01Z","timestamp":1790742661270,"version":"4.1.0"},"reference-count":65,"publisher":"Wiley","issue":"3","license":[{"start":{"date-parts":[[2022,1,25]],"date-time":"2022-01-25T00:00:00Z","timestamp":1643068800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Annals of Neurology"],"published-print":{"date-parts":[[2022,3]]},"abstract":"<jats:p>Since 2016, 3 innovative therapies for spinal muscular atrophy (SMA) have changed the face of the disease. Although these therapies often result in remarkable improvements in infants and children, benefits in adults are modest and treatment is not curative. Concerns have been raised about the enormous costs of these medications, the ultimate burden to taxpayers, and the costs to society of withholding treatments and sacrificing or disadvantaging some individuals. Physicians are best positioned to serve our patients by carefully considering the costs, benefits, implications for quality of life (QOL), and the interplay of these factors within the framework of core ethical principles that guide clinical care. ANN NEUROL 2022;91:305\u2013316<\/jats:p>","DOI":"10.1002\/ana.26299","type":"journal-article","created":{"date-parts":[[2022,1,3]],"date-time":"2022-01-03T23:49:02Z","timestamp":1641253742000},"page":"305-316","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":33,"title":["Ethical Perspectives on Treatment Options with Spinal Muscular Atrophy Patients"],"prefix":"10.1002","volume":"91","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5445-5965","authenticated-orcid":false,"given":"Crystal J. J.","family":"Yeo","sequence":"first","affiliation":[{"name":"Boston Children's Hospital, Harvard Medical School  Boston MA USA"},{"name":"School of Medicine, Medical Sciences, and Nutrition University of Aberdeen  Aberdeen UK"},{"name":"Lee Kong Chian School of Medicine Imperial College London and NTU  Singapore Singapore"},{"name":"Agency for Science Technology and Research (A*STAR)  Singapore Singapore"},{"name":"Feinberg School of Medicine Northwestern University  Chicago IL USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zachary","family":"Simmons","sequence":"additional","affiliation":[{"name":"Penn State Health Milton S. Hershey Medical Center  Hershey PA USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Darryl C.","family":"De Vivo","sequence":"additional","affiliation":[{"name":"Columbia University  New York NY USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Basil T.","family":"Darras","sequence":"additional","affiliation":[{"name":"Boston Children's Hospital, Harvard Medical School  Boston MA USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2022,1,25]]},"reference":[{"key":"e_1_2_13_2_1","unstructured":"Office of the Commissioner US Food and Drug Administration.FDA approves oral treatment for spinal muscular atrophy. August 7 2020. Available at:www.fda.gov\/news-events\/press-announcements\/fda-approves-oral-treatment-spinal-muscular-atrophy. Accessed September 1 2021."},{"key":"e_1_2_13_3_1","unstructured":"Spinraza prescribing information. Cambridge MA: Biogen 2016."},{"key":"e_1_2_13_4_1","unstructured":"Zolgensma prescribing information Bannockburn IL: AveXis2019."},{"key":"e_1_2_13_5_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1706198"},{"key":"e_1_2_13_6_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2102047"},{"key":"e_1_2_13_7_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1702752"},{"key":"e_1_2_13_8_1","doi-asserted-by":"publisher","DOI":"10.1111\/bioe.12695"},{"key":"e_1_2_13_9_1","unstructured":"Institute for Clinical and Economic Review.Spinraza\u00ae and Zolgensma\u00ae for spinal muscular atrophy: effectiveness and value.2018. April 3 2019. Available at:https:\/\/icer.org\/wp-content\/uploads\/2020\/10\/ICER_SMA_Final_Evidence_Report_110220.pdf. Accessed September 1 2021."},{"key":"e_1_2_13_10_1","unstructured":"FidlerB.First oral drug for spinal muscular atrophy approved by FDA. 2020. Available at:www.biopharmadive.com\/news\/roche-ptc-risdiplam-approval-spinal-muscular-atrophy\/583167. Accessed September 1 2021."},{"key":"e_1_2_13_11_1","volume-title":"Principles of biomedical ethics","author":"Beauchamp TL","year":"2001"},{"key":"e_1_2_13_12_1","doi-asserted-by":"publisher","DOI":"10.1038\/ejhg.2011.134"},{"key":"e_1_2_13_13_1","doi-asserted-by":"publisher","DOI":"10.1002\/(SICI)1098-1004(200003)15:3<228::AID-HUMU3>3.0.CO;2-9"},{"key":"e_1_2_13_14_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(20)30037-5"},{"key":"e_1_2_13_15_1","doi-asserted-by":"publisher","DOI":"10.1002\/mus.26769"},{"key":"e_1_2_13_16_1","doi-asserted-by":"publisher","DOI":"10.3233\/JND-190416"},{"key":"e_1_2_13_17_1","doi-asserted-by":"publisher","DOI":"10.3233\/JND-190453"},{"key":"e_1_2_13_18_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0092-8674(00)80368-2"},{"key":"e_1_2_13_19_1","doi-asserted-by":"publisher","DOI":"10.1093\/hmg\/ddq300"},{"key":"e_1_2_13_20_1","doi-asserted-by":"publisher","DOI":"10.1083\/jcb.152.5.1107"},{"key":"e_1_2_13_21_1","doi-asserted-by":"publisher","DOI":"10.1093\/hmg\/ddv127"},{"key":"e_1_2_13_22_1","doi-asserted-by":"publisher","DOI":"10.1038\/nature10485"},{"key":"e_1_2_13_23_1","first-page":"932","article-title":"SMN deficiency negatively impacts red pulp macrophages and spleen development in mouse models of spinal muscular atrophy","volume":"26","author":"Khairallah M\u2010T","year":"2017","journal-title":"Hum Mol Genet"},{"key":"e_1_2_13_24_1","doi-asserted-by":"publisher","DOI":"10.1002\/path.2566"},{"key":"e_1_2_13_25_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.pediatrneurol.2020.01.003"},{"key":"e_1_2_13_26_1","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000007527"},{"key":"e_1_2_13_27_1","unstructured":"PascualSI DayJW FinkelRS et al.Ongoing phase 2\/3 DEVOTE (232SM203) randomized controlled study to explore high\u2010dose nusinersen in SMA: part a interim results and part B enrollment update. Paper presented at: MDA Virtual Clinical and Scientific Conference; March 15\u2013182021. Available at: https:\/\/www.neurologylive.com\/view\/nusinersen\u2010safety\u2010demonstrated\u2010devote\u2010phase\u20102\u20103\u2010sma."},{"key":"e_1_2_13_28_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(21)00001-6"},{"key":"e_1_2_13_29_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.pediatrneurol.2019.05.005"},{"key":"e_1_2_13_30_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jpeds.2020.11.054"},{"key":"e_1_2_13_31_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamaneurol.2021.1272"},{"key":"e_1_2_13_32_1","doi-asserted-by":"publisher","DOI":"10.1038\/gt.2015.112"},{"key":"e_1_2_13_33_1","doi-asserted-by":"publisher","DOI":"10.1038\/nbt.1515"},{"key":"e_1_2_13_34_1","doi-asserted-by":"publisher","DOI":"10.1038\/mt.2016.17"},{"key":"e_1_2_13_35_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ymthe.2021.01.007"},{"key":"e_1_2_13_36_1","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.m580"},{"key":"e_1_2_13_37_1","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000008207"},{"key":"e_1_2_13_38_1","unstructured":"Biogen.Biogen announces first patient treated in RESPOND study evaluating benefit of SPINRAZA\u00ae (nusinersen) in patients treated with Zolgensma\u00ae (onasemnogene abeparvovec). January 8 2021. Available at:investors.biogen.com\/news\u2010releases\/news\u2010release\u2010details\/biogen\u2010announces\u2010first\u2010patient\u2010treated\u2010respond\u2010study\u2010evaluating. Accessed September 1 2021."},{"key":"e_1_2_13_39_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2009965"},{"key":"e_1_2_13_40_1","article-title":"SUNFISH part 2: efficacy and safety of risdiplam (RG7916) in patients with type 2 or non\u2010ambulant type 3 spinal muscular atrophy (SMA). Presented at the American Academy of Neurology conference 2020","volume":"94","author":"Mercuri E","year":"2020","journal-title":"Neurology"},{"key":"e_1_2_13_41_1","doi-asserted-by":"publisher","DOI":"10.1021\/acs.jmedchem.8b00741"},{"key":"e_1_2_13_42_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.genhosppsych.2014.02.013"},{"key":"e_1_2_13_43_1","volume-title":"Health literacy: a prescription to end confusion","author":"Institute of Medicine (US) Committee on Health Literacy","year":"2004"},{"key":"e_1_2_13_44_1","doi-asserted-by":"publisher","DOI":"10.1089\/hum.2014.030"},{"key":"e_1_2_13_45_1","doi-asserted-by":"publisher","DOI":"10.1093\/hmg\/ddaa146"},{"key":"e_1_2_13_46_1","doi-asserted-by":"publisher","DOI":"10.1080\/13543784.2021.1904889"},{"key":"e_1_2_13_47_1","doi-asserted-by":"publisher","DOI":"10.1002\/ana.20473"},{"key":"e_1_2_13_48_1","doi-asserted-by":"publisher","DOI":"10.2147\/TCRM.S172291"},{"key":"e_1_2_13_49_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.nmd.2019.09.007"},{"key":"e_1_2_13_50_1","unstructured":"Novartis.New Zolgensma data demonstrate age\u2010appropriate development when used presymptomatically and rapid clinically meaningful efficacy in symptomatic children even those with severe SMA at baseline. News release. June 18 2021. Available at:https:\/\/www.novartis.com\/news\/media-releases\/new-zolgensma-data-demonstrate-age-appropriate-development-when-used-presymptomatically-and-rapid-clinically-meaningful-efficacy-symptomatic-children-even-those-severe-sma-baseline. Accessed June 21 2021."},{"key":"e_1_2_13_51_1","unstructured":"SwobodaKJ SansoneVA deVivoDC et al.Preserved swallowing function in infants who initiated nusinersen treatment in the presymptomatic stage of SMA: results from the NURTURE study. Paper presented at: MDA Virtual Clinical and Scientific Conference; March 15\u201318 2021."},{"key":"e_1_2_13_52_1","doi-asserted-by":"publisher","DOI":"10.1002\/ana.25930"},{"key":"e_1_2_13_53_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00415-013-7068-y"},{"key":"e_1_2_13_54_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jval.2018.01.008"},{"key":"e_1_2_13_55_1","doi-asserted-by":"publisher","DOI":"10.1186\/s12883-017-0853-y"},{"key":"e_1_2_13_56_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.nmd.2017.01.018"},{"key":"e_1_2_13_57_1","doi-asserted-by":"publisher","DOI":"10.1186\/s13023-020-1339-3"},{"key":"e_1_2_13_58_1","doi-asserted-by":"publisher","DOI":"10.3233\/JND-200610"},{"key":"e_1_2_13_59_1","doi-asserted-by":"publisher","DOI":"10.1002\/mus.27380"},{"key":"e_1_2_13_60_1","doi-asserted-by":"publisher","DOI":"10.2165\/00019053-200826090-00004"},{"key":"e_1_2_13_61_1","unstructured":"Institute for Clinical and Economic Review. 2020\u20132023 value assessment framework. 31 January 31 2020. Available at:https:\/\/icer.org\/wp-content\/uploads\/2020\/10\/ICER_2020_2023_VAF_102220.pdf. Accessed September 1 2021."},{"key":"e_1_2_13_62_1","unstructured":"Institute for Clinical and Economic Review. A look at Spinraza and Zolgensma for spinal muscular atrophy. April 3 2019. Available at:https:\/\/icer.org\/wp-content\/uploads\/2020\/10\/SMA-RAAG_060519.pdf. Accessed September 1 2021."},{"key":"e_1_2_13_63_1","unstructured":"National Institute for Health and Care Excellence. Onasemnogene abeparvovec for treating spinal muscular atrophy [ID1473]: evaluation report. August 19 2019. Available at:https:\/\/www.nice.org.uk\/guidance\/hst15\/evidence\/evaluation-consultation-committee-papers-pdf-9191287693. Accessed September 1 2021."},{"key":"e_1_2_13_64_1","unstructured":"National Institute for Health and Care Excellence. Nusinersen for treating spinal muscular atrophy: technology appraisal guidance [TA588]. July 24 2019. Available at:https:\/\/www.nice.org.uk\/guidance\/ta588\/evidence. Accessed September 1 2021."},{"key":"e_1_2_13_65_1","unstructured":"National Institute for Health and Care Excellence. Single technology appraisal: risdiplam for treating spinal muscular atrophy in children and adults [ID1631]. October 2020. Available at:https:\/\/www.nice.org.uk\/guidance\/gid-ta10612\/documents\/committee-papers. Accessed September 1 2021."},{"key":"e_1_2_13_66_1","doi-asserted-by":"publisher","DOI":"10.1186\/1750-1172-6-42"}],"container-title":["Annals of Neurology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/ana.26299","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1002\/ana.26299","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/ana.26299","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,8,27]],"date-time":"2023-08-27T10:54:17Z","timestamp":1693133657000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/ana.26299"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,1,25]]},"references-count":65,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2022,3]]}},"alternative-id":["10.1002\/ana.26299"],"URL":"https:\/\/doi.org\/10.1002\/ana.26299","archive":["Portico"],"relation":{},"ISSN":["0364-5134","1531-8249"],"issn-type":[{"value":"0364-5134","type":"print"},{"value":"1531-8249","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,1,25]]},"assertion":[{"value":"2021-09-20","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2021-12-31","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2022-01-25","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}